Given the widespread impact of COVID-19, initial public offering (IPO) exit activity has effectively ground to a halt in the U.S. With the U.S. presidential election scheduled for November, most planned IPO activity is expected to be pushed back until 2021. Biotech companies will likely be the primary exception, regardless of whether they are focused on COVID-19 treatments or on other diseases.
While mainstream IPO activity might be non-existent for the remainder of 2020, there could be increasing merger and acquisition (M&A) activity in the U.S. over the same timeframe, particularly related to companies without the runway to delay their exit into 2021. With the increasing scrutiny of companies looking to IPO, startups that do not expect their financial performance to improve considerably over the next year could also turn their attention to pursuing buyers. Both private equity (PE) firms and corporates will likely be hunting for strategic acquisition opportunities given companies will likely be more cost-effective given current market challenges.
Join KPMG Private Enterprise for our Semiannual IPO and M&A Outlook Webcast where professionals from KPMG and Goldman Sachs will examine the activity and trends that shaped the IPO and M&A landscape in the first half of 2020 and share their insights on what’s in store for the remainder of the year.
Why attend? To gain fresh perspectives on:
- The state of the IPO and M&A market and outlook for the second half of 2020
- Impact of COVID-19 on the venture capital markets
- U.S. venture capital activity and anticipated trends for the remainder of 2020